Close
Almac
Achema middle east

Biocair Transports Plasmids For COVID-19 Research in South Africa

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Proactive Risk Management as a Core Capability in Pharma Development

Risk management in pharma is often treated as a reactive compliance box-ticking exercise. This article argues for reframing risk as a strategic competitive advantage. It details proactive frameworks like the "Excipient Exclusion Filter," Decision Quality (DQ) matrices, and "pre-mortem" analyses that allow development teams to anticipate failure modes and engineer them out of the pipeline before they occur.

Rethinking Pipeline Value Beyond Peak Sales Forecasts

The traditional reliance on risk-adjusted Net Present Value (rNPV) and peak sales forecasts is failing to capture the true potential of modern pharmaceutical assets, particularly platform technologies. This article introduces holistic valuation frameworks like Real Options Analysis (ROA) and the Platform VISTA model, arguing for a shift toward valuing "strategic fit," "lifecycle potential," and the intangible equity of innovation engines.

Building Resilient Pharma Portfolios in an Era of Scientific and Market Uncertainty

Pharmaceutical companies are radically redesigning portfolio strategies to survive a "triple threat" environment of scientific complexity, regulatory upheaval like the IRA, and capital scarcity. This analysis explores the shift from efficiency-driven models to resilience-first frameworks, detailing how leaders are embedding optionality into pipelines, embracing modality agnosticism, and using dynamic resource allocation to thrive amidst volatility.
- Advertisement -

Biocair, a global specialist in life sciences logistics, was selected to transport time-critical plasmids from the USA to the Africa Health Research Institute (AHRI) in Durban, South Africa.

AHRI Faculty Member and Research Group Leader at the Max Planck Institute for Infection Biology in Berlin, Dr Alex Sigal, highlighted the importance of the materials being transported and the standard of service provided by Biocair:

“These reagents that Biocair delivered to us from the USA, at record speed and surmounting considerable obstacles because of the lockdown both in the USA and in South Africa, will allow us to understand the immune response of people in KwaZulu-Natalto SARS-CoV-2, the virus causing COVID-19.

This vital shipment contained the human gene fragment which allows the virus to infect human cells. The shipment also contained a set of gene fragments allowing us to make non-infectious SARS-CoV-2 that is fluorescent.

The combination of both these reagents will allow us to test how quickly individuals in South Africa, including those diagnosed with HIV, are able to fight SARS-CoV-2 infection by producing antibodies which prevent the virus from infecting new cells.”

In a recent webinar sponsored by Biocair and hosted by the South African Clinical Research Association, Professor Salim S. Abdool Karim, FRS, Chair of the South African Ministerial Advisory Committee on COVID-19, discussed the current situation and state of play in South Africa, in responding to the pandemic.

Despite the unprecedented situation we currently find ourselves in, Biocair is fully committed to delivering continuity of service within the life sciences supply chain. Contact your local office to see how Biocair can support your logistics.

Latest stories

Related stories

Proactive Risk Management as a Core Capability in Pharma Development

Risk management in pharma is often treated as a reactive compliance box-ticking exercise. This article argues for reframing risk as a strategic competitive advantage. It details proactive frameworks like the "Excipient Exclusion Filter," Decision Quality (DQ) matrices, and "pre-mortem" analyses that allow development teams to anticipate failure modes and engineer them out of the pipeline before they occur.

Rethinking Pipeline Value Beyond Peak Sales Forecasts

The traditional reliance on risk-adjusted Net Present Value (rNPV) and peak sales forecasts is failing to capture the true potential of modern pharmaceutical assets, particularly platform technologies. This article introduces holistic valuation frameworks like Real Options Analysis (ROA) and the Platform VISTA model, arguing for a shift toward valuing "strategic fit," "lifecycle potential," and the intangible equity of innovation engines.

Building Resilient Pharma Portfolios in an Era of Scientific and Market Uncertainty

Pharmaceutical companies are radically redesigning portfolio strategies to survive a "triple threat" environment of scientific complexity, regulatory upheaval like the IRA, and capital scarcity. This analysis explores the shift from efficiency-driven models to resilience-first frameworks, detailing how leaders are embedding optionality into pipelines, embracing modality agnosticism, and using dynamic resource allocation to thrive amidst volatility.

AI-Crafted Pill Succeeds Trials of Plaque Psoriasis Patients

Takeda Pharmaceutical from Japan said on December 17, 2025,...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »